CAS: 193149-74-5; 2-(3-(2-Methoxy-4-Nitrophenyl)-2-(4-Nitrophenyl)-2H-Tetrazol-3-Ium-5-yl)-5-Sulfobenzenesulfonate, Sodium Salt

专利信息

专利号:US-2024173256-A1
优先权日:2022-11-29
标 题:Hdl mimicking targeted drug delivery system for the treatment of solid tumors
发明人：SABNIS NIRUPAMA; LACKO ANDRAS; FUDALA RAFAL
权利人:UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER
摘要:The present disclosure is directed to an SR-B1-targeting nanomicelle and compositions, methods of synthesis and methods of use thereof. The nanomicelle may be an HDL-mimetic drug delivery system and may be cross-linked with DSS. The composition may contain a therapeutic agent with the ability to treat cancers, especially sarcomas.

专利号:WO-2023245091-A1
优先权日:2022-06-15
标题 :Pyridazinone-derived compounds for the modulation of myc and for medical uses
发明人：ADANVE BERTRAND; NG YAO ZONG; LAI JONATHAN
权利人:GENETIC INTELLIGENCE INC
摘要:Compositions, systems, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression or activity of MYC in a cell, animal or human subject. Such compositions, systems, and methods are useful to prevent, ameliorate, or treat diseases, including cell proliferation diseases and disorders such as cancer, particularly MYC-driven cancer. Compositions are described comprising a compound of formula (I), as well as pharmaceutical compositions or medicaments thereof. Also described are methods of use of such compositions to treat, prevent, or ameliorate diseases, including cell proliferation diseases and disorders such as cancer, in particular MYC-driven cancer. Compositions comprising conjugates and complexes of a compound of formula (I) are also described, which are also useful in the methods described herein. Methods are described comprising the use of a compound of formula (I), or pharmaceutical compositions thereof, for the reduction or inhibition of MYC expression or activity, and/or for achieving one or more desirable phenotypic outcomes such as, for example, decrease in cancer cell growth or proliferation, decrease in cancer cell viability, decrease in tumor volume (i.e., tumor regression), decrease in cancer metastasis, increase in animal or human survival, or other desired outcome with respect to particular phenotypes (e.g., body weight, metabolism, etc.). Related medicaments, kits, and methods of delivery of such compositions are described. Methods are also described for the development, manufacture, and/or synthesis of a compound of formula (I), as well as pharmaceutical compositions thereof. Furthermore, methods for diagnostics and testing comprising detecting MYC expression or activity levels, as well as compositions comprising kits for diagnostics and testing, are described.

专利号:US-2025268860-A1
优先权日:2021-10-22
标 题 :Composition for use in the cutaneous synthesis of hyaluronic acid, in an immuno-cutaneous response and to improve skin
发明人：BERNARD PHILIPPE
权利人:JR
摘要:A composition comprising baicalin or a derivative thereof, more particularly in combination with chlorogenic acid or a derivative thereof, as well as the cosmetic use of such a composition and its medical applications.

专利号:US-2025066826-A1
优先权日:2023-08-21
标 题 :Artificial synthesis method for malonyl-coenzyme a (coa) and use thereof
发明人：TAN ZAIGAO; LIU TIANGANG; LI JIAN
权利人:UNIV SHANGHAI JIAOTONG
摘要:An artificial synthesis method for malonyl-CoA and use thereof are provided. By means of heterologous expression of an aminotransferase and a malonyl-CoA reductase, an artificial synthesis pathway for synthesizing malonyl-CoA by using β-alanine (β-ala) as a precursor is constructed as follows: firstly, under catalysis of a transaminase, β-ala transfers amino groups to α-ketonic acid (such as pyruvic acid, oxaloacetic acid, or α-ketoglutaric acid, etc.), to form an intermediate product 3-oxopropanoate and a corresponding amino acid; the 3-oxopropanoate generates malonyl-CoA under the action of the malonyl-CoA reductase. This pathway addresses the defects of the natural malonyl-CoA synthesis pathway, such as low carbon utilization, consumption of energy substance ATP, release of greenhouse gas CO 2 , and strict regulation of pathway enzymes, a pyruvate dehydrogenase (PDH) and an acetyl-CoA carboxylase (ACC), thereby achieving high yielding of products using malonyl-CoA as a precursor, including flaviolin, octanoic acid, phloroglucinol, pentadecaheptaene, natamycin, and spinosad.

专利号:WO-2023067251-A1
优先权日:2021-10-22
标 题:Composition for use in the cutaneous synthesis of hyaluronic acid, in an immuno-cutaneous response and to improve skin

专利号:WO-2024193321-A1
优先权日:2023-03-17
标 题 :Use of glyt1 inhibitor in treatment of organ fibrosis
发明人：LI WEIDONG; LI XUEMIN; QIU JIALI; YANG KE; FU YUN; LI SHEN
权利人:UNIV TIANJIN MEDICAL
摘要:Use of a GLYT1 inhibitor in the treatment of organ fibrosis, especially the use in the preparation of a drug for treating organ fibrosis. By taking GLYT1 as a target, a GLYT1 inhibitor is used to inhibit a glycine transporter GLYT1 to achieve the treatment of fibrotic organs. The drug containing the GLYT1 inhibitor is particularly suitable for the treatment of pulmonary fibrosis. By inhibiting the glycine transporter GLYT1 by means of the GLYT1 inhibitor, collagen synthesis is reduced, so that pulmonary fibrosis caused by bleomycin can be obviously improved, and the formed pulmonary fibrosis is also obviously improved; and by taking GLYT1 as the target, the solution has a small influence on other physiological functions.